Kynurenine Pathway Metabolites as Biomarkers for Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) currently lacks a robust and well-defined biomarker that can 1) assess the progression of the disease, 2) predict and/or delineate the various clinical subtypes, and 3) evaluate or predict a patient’s response to treatments. The kynurenine Pathway (KP) of tryptoph...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Vanessa X., Guillemin, Gilles J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764462/
https://www.ncbi.nlm.nih.gov/pubmed/31616242
http://dx.doi.org/10.3389/fnins.2019.01013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764462/
https://www.ncbi.nlm.nih.gov/pubmed/31616242
http://dx.doi.org/10.3389/fnins.2019.01013

Ejemplares similares